<SEC-DOCUMENT>0001193125-24-087858.txt : 20240405
<SEC-HEADER>0001193125-24-087858.hdr.sgml : 20240405
<ACCEPTANCE-DATETIME>20240405060554
ACCESSION NUMBER:		0001193125-24-087858
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240405
DATE AS OF CHANGE:		20240405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261095
		FILM NUMBER:		24824669

	BUSINESS ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d800418d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENT NO. 1 DATED APRIL&nbsp;5, 2024 TO</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT DATED DECEMBER&nbsp;22, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated November&nbsp;29, 2021)</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-261095</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g800418g0323102309669.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Supplement No.&nbsp;1 to
Prospectus Supplement (this &#147;Supplement&#148;) supplements and amends the Prospectus Supplement dated December&nbsp;22, 2021 (the &#147;Prospectus Supplement&#148;). This Supplement should be read in conjunction with the Prospectus Supplement
and the Prospectus dated November&nbsp;29, 2021. This Supplement is qualified by reference to the Prospectus Supplement, except to the extent that the information presented herein supersedes the information contained in the Prospectus Supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2021, we entered into a Sales Agreement, dated November&nbsp;15, 2021 (the &#147;Sales Agreement&#148;), with Cowen and Company, LLC
(&#147;TD Cowen&#148;) relating to shares of our common stock offered by the Prospectus Supplement dated December&nbsp;22, 2021. In accordance with the terms of the Sales Agreement, we could offer and sell shares of our common stock having an
aggregate offering price of up to $50,00,000 from time to time through TD Cowen pursuant to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> transactions (&#147;ATM&#148;). As of the date of this
Supplement, we have sold an aggregate of 6,403,703 shares of our common stock pursuant to the Sales Agreement for aggregate gross proceeds of $21,772,134.37. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of this Supplement is to reduce the size of the continuous offering by us under the Prospectus Supplement to up to $100,000 of shares, effective
on April&nbsp;5, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if this prospectus and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this Supplement No.&nbsp;1 to the Prospectus Supplement is April 5, 2024. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g800418g0323102309669.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800418g0323102309669.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K .D# 2(  A$! Q$!_\0
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:6WM((X($SMCC4*HSSP!4U<KM?0ZE>VI__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
